Breaking News, Collaborations & Alliances

VTU Technology and Biomay Sign License Agreement

Biomay to apply VTU Pichia strains for the production of recombinant allergens

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

VTU Technology and Biomay, two leading Austrian biotech companies, have entered into a licensing agreement for the production of recombinant allergens. VTU Technology, currently offering a broad and comprehensive Pichia pastoris expression platform, grants Biomay access to VTU´s Pichia pastoris protein expression technology. Biomay, a global leader in allergy immunotherapy, will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters